Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
You may also be interested in...
Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.